Cathal Friel reverses Open Orphan into listed Venn Life Sciences - Raglan Capital

Home
About Us
Selected Transactions
Raglan IPO Projects
- Raglan Pharmaceutical & Life Science Projects
- Raglan Natural Resources
News
Contact us

Search

Cathal Friel reverses Open Orphan into listed Venn Life Sciences

Home
2019
Cathal Friel reverses Open Orphan into listed Venn Life Sciences

Recent News

Open Orphan signs €4.4m contract with global company
Open Orphan wins €4m contract to conduct trial for new RSV treatment
Open Orphan deal to generate ‘significant revenue’ for Venn Life Sciences
Open Orphan signs deal to carry out Covid-19 vaccine trial
Open Orphan agrees contract for Covid-19 vaccine trial
Open Orphan wins contact for Covid-19 vaccine trial

Cathal Friel reverses Open Orphan into listed Venn Life Sciences

10th May 2019

https://otp.investis.com/clients/uk/amryt_pharmaceuticals_dac1/rns/regulatory-story.aspx?cid=1375&newsid=1218097

Prev
Next

Join us for our newsletters

Raglan Capital
18 Fitzwilliam Place, Dublin 2.
T: +353 1 6440007
E: info@raglancapital.ie

Contact us
Careers
Privacy Policy
Cookie policy (EU)

Join us for our newsletters

Raglan Capital
18 Fitzwilliam Place, Dublin 2.
T: +353 1 6440007
E: info@raglancapital.ie

Contact us
Careers
Privacy Policy
Cookie policy (EU)

© 2020 Raglan Capital. All rights reserved

Privacy Preference Center

Privacy Preferences